Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jun 1, 2011


Affymetrix announced this week that President and CEO Kevin King will step down at the end of June to "pursue other interests."

King will be replaced by Dionex President and CEO Frank Witney, who some years ago, served as Affymetrix's executive VP and COO.

BioMarker Strategies announced that Douglas Clark will become the company's chief medical officer and acting CEO starting July 1. Clark is currently a professor of pathology and oncology at The Johns Hopkins Medical Institutions, where from 2002 to 2010 he served as the director of the cytopathology division. He will be taking a leave of absence from Johns Hopkins to join BioMarker Strategies full time.

Additionally, BioMarker Strategies has appointed Glenn Miller, VP and head of strategy, portfolio, and alliances for personalized healthcare & biomarkers at AstraZeneca Pharmaceuticals, as the chairman of its board of directors. Miller previously served on BioMarker Strategies' scientific advisory board.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.